Business
Ocular Therapeutix™ To Present Pre-Clinical Data at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting
BEDFORD, Mass.--(BUSINESS WIRE)-- Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and
About this update from Ocular Therapeutix, Inc.
[{"type":"text","content":" BEDFORD, Mass.--(BUSINESS WIRE)--\nOcular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, announced two scientific presentations at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting being held May 16-19, 2022 in Washington, D.C. and virtually.\n\n“We have demonstrated the flexibility of our hydrogel platform across multiple ophthalmic indications and are excited to be presenting data using the hydrogel platform in gene therapy delivery at the ASGCT Annual Meeting,” commented Michael Goldstein, MD, MBA, President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix. “The pre-clinical studies highlight data demonstrating our hydrogel platform’s potential to safely and durably deliver an adeno-associated virus (AAV) gene therapy in animal models.”\n\nOcular Therapeutix Presentations at ASGCT:\n\n\nTitle: Reduced Ocular Inflammation and Improved GFP Expression in Rabbits with Controlled Release of Adeno-Associated Virus from Degradable Hydrogel Implants\nSession Title: Ophthalmic and Auditory Diseases\nSession Date/Times: Thursday May 19, 2022 11:00 AM – 11:15 AM ET\nPresentation type: Podium Presentation\nPresenter: Steven Lu, PhD and Meryem Pehlivaner, PhD\n\n\n\nTitle: Development of Hydrogel Implants for the Sustained Delivery of Adeno-Associated Viruses in Ocular Gene Therapy\nSession Title: Ophthalmic and Auditory Diseases\nSession Date/Times: Monday, May 16, 2022 5:50 PM - 6:30 PM ET\nPresentation type: Poster (Board No. M-167)\nPresenter: Steven Lu, PhD\n\n\nAbout Ocular Therapeutix, Inc.\n\nOcular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets includes OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other ret...